Assessment of the impact of introducing fetal fibronectin assay in the management of preterm labour at Middlemore Hospital, New Zealand

Pathology

Volumn 37, Issue 3, 2005, Pages 226-230

  Musaad, Samarina M A ^a,b   Melson, C Louise ^a   Boswell, D Ross ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Cost savings; Fetal fibronectin; Preterm labour

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; NIFEDIPINE; STEROID;

ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; COST; COST CONTROL; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; NEW ZEALAND; PREDICTION; PREMATURE LABOR; TOCOLYSIS; VAGINA SECRETION;

EID: 21744452196     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500099056     Document Type: Article

References (40)

1. Hirschi SD, Gray SD, Thibeault SL. Fibronectin: An interesting vocal fold protein. J Voice 2002; 16: 310-6.
2. Filenius S, Tervo T, Virtanen I. Production of fibronectin and tenascin isoforms and their role in the adhesion of human immortalized corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44: 3317-25.
3. Kozaki T, Matsui Y, Gu J, et al. Recombinant expression and characterization of a novel fibronectin isoform expressed in cartilaginous tissues. J Biol Chem 2003; 278: 50546-53.
4. Lacewood CJ, Senyei AE, Dische R, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325: 669-74.
5. Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991; 138: 537-43.
6. Honest H, Bachmann L, Gupta J, et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002; 325: 301.
7. Joffe GM, Jacques D, Bemis-Heys, et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999; 180: 581-6.
8. Lockwood CJ. Recent advances in elucidating the pathogenesis of preterm delivery, the detection of patients at risk, and preventative therapies. Curr Opin Obstet Gynecol 1994; 6: 7-18.
9. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997; 177: 13-8.
10. Goldenberg RL, Mercer BM, Iams JD, et al. The Preterm Prediction Study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1997; 177: 8-12.
11. Iams JD, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1998; 178: 1035-40.
12. Bartnicki J, Casal D, Kreaden US, Saling E, Vetter K. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am J Obstet Gynecol 1996; 174: 971-4.
13. Burrus DR, Ernest JM, Veille JC. Fetal fibronectin, interleukin-6 and C-reactive protein are useful in establishing prognostic subcategories of idiopathic preterm labor. Am J Obstet Gynecol 1995; 173: 1258-62.
14. McGregor JA, Goodwin TM, Kreaden US, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995; 173: 141-5.
15. Inglis SR, Jeremias J, Kuno K, et al. Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am J Obstet Gynecol 1994; 171: 5-10.
16. Morrison JC, Allbert JR, McLaughlin BN, Whitworth NS, Roberts WE, Martin RW. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol 1993; 168: 538-42.
17. Creasy RK, Resnik R, editors. Maternal Fetal Medicine: Principles and Practice. 3rd ed. Philadelphia: Saunders, 1995.
18. Morrison JC, Neaf RW 3rd, Botti JJ, Katz M, Belluomini JM, McLaughlin BN. Prediction of spontaneous preterm birth by fetal fibronectin and uterine activity. Obstet Gynecol 1996; 87: 649-55.
19. Lockwood CJ, Wein R, Lapinski R, et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol 1993; 169: 798-804.
20. Leeson SC, Maresh MJA, Martindale EA, et al. Detection of fetal fibronectin as a predictor of preterm delivery in high risk asymptomatic pregnancies. Br J Obstet Gynaecol 1996; 103: 48-53.
21. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol 1996; 87: 643-8.
22. Matsuura H, Takio K, Titani K, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 1988; 263: 3314-22.
23. Nageotte MP, Casal D, Senyei AE. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol 1994; 170: 20-5.
24. Revah A, Sue-A-Quan A, Hannah M. Fetal fibronectin as a predictor of preterm birth: a systematic review of the literature. Am J Obstet Gynecol 1997; 176: S53 (abstr).
25. Chien PFW, Khan KS, Ogston S, Owen P. The diagnostic accuracy of cervico-vaginal fetal fibronectin in predicting preterm delivery: an overview. Br J Obstet Gynaecol 1997; 104: 436-44.
26. Ascarelli MH, Morrison JC. Use of fetal fibronectin in clinical practice. Obstet Gynecol Surv 1997; 52: S1-12.
27. Benattar C, Taieb J, Femandez H, Lindendaum A, Frydman R, Ville Y. Rapid fetal fibronectin swab-test in preterm labour patients treated by betamimetics. Eur J Obstet Gynecol Reprod Biol 1997; 72: 131-5.
28. Greenhagen JB, Van Wagoner J, Dudley D, et al. Value of fetal fibronectin as a predictor of preterm delivery for a low-risk population. Am J Obstet Gynecol 1996; 175: 1054-6.
29. Parker J, Bell R, Brennecke S. Fetal fibronectin in the cervicovaginal fluid of women with threatened preterm labour as a predictor of delivery before 34 weeks gestation. Aust N Z J Obstet Gynaecol 1995; 35: 257-61.
30. Maternal and Child Health Consortium. Confidential enquiries into stillbirths and deaths in infancy (CESDI): 6th annual report. London: Stationery Office.
31. Peters KD, Kochanek KD, Murphy SL. Deaths: final data for 1996. Natl Vital Stat Rep 1998; 47: 1-100.
32. Department of Health (UK). NHS maternity statistics, England: 1989-90 to 1994-95. London: Stationery Office, 1997.
33. Craig ED, Thompson JM, Mitchell EA. Socioecconomic status and preterm birth: New Zealand trends 1980 to 1999. Arch Dis Child Fetal Neonatal Educ 2002; 86: F142-6.
34. Leitich H, Egarter C, Kaider A, et al. Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-analysis. Am J Obstet Gynecol 1999; 180: 1169-76.
35. Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003; 101: 402-12.
36. Maymon R, Bahari C, Moroz C. Placental isoferitin measured by specific monoclonal antibody as a predictive marker for preterm contraction outcome. Obstet Gynecol 1989; 74: 597-9.
37. Wasmoen TL, Coulam CB, Leiferman KM, Gleich GJ. Increases of plasma eosinophil major basic protein levels late in pregnancy predict onset of labour. Proc Natl Acad Sci USA 1987; 84: 3029-32.
38. Giles W, Bisits A, Knox M, et al. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000; 182: 439-42.
39. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labour management in a tertiary care centre. Am J Obstet Gynecol 2004; 190: 358-62.
40. Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labour affect physician behaviour and health care costs? A randomised trial. Am J Obstet Gynecol 2004; 191: 235-40.